Cefotaxime (CTX) is a beta-lactam antibiotic classified as a third-generation cephalosporin, which was first synthesized in 1976 and is FDA approved for the treatment of gram-positive, gram-negative, and anaerobic bacteria. Its broad-spectrum antibacterial activity is useful in treating the susceptible strains of bacteria affecting the lower respiratory tract, genito-urinary tract, central nervous system, intra-abdominal infections, bone and joint infections, skin infections, gynecologic infections, and septicemia. Cefotaxime(CTX) may also be used prophylactically prior to surgery to prevent surgical infections.
Among the susceptible strains, Enterobacteriaceae is particularly sensitive to cefotaxime (CTX) and may treat multi-drug resistant strains of Enterobacteriaceae. Although it has a broad spectrum of bactericidal activity, it is not as effective against pseudomonas aeruginosa infections when compared to other third-generation antibiotics and is not recommended as monotherapy. Intramuscular treatment with cefotaxime(CTX) for sexually transmitted infections with Neisseria gonorrhoeae has shown a positive outcome in both men and women. Cefotaxime has beneficial therapeutic activity treating pneumonia affecting the lower respiratory tract primarily caused by Gram-negative bacilli, and the bactericidal agent has shown significant efficacy in the treatment of complicated infections affecting the urinary tract.
A favorable characteristic of cefotaxime(CTX), when compared with the other cephalosporins, is that it does not cause a notable occurrence of coagulopathies and pseudocholelithiasis. Trials conducted comparing cefotaxime with the third-generation cephalosporin ceftriaxone have exhibited similar clinical efficiency. Clinical trials have also shown 75% to 100% resolution in hospitalized patients with moderate to severe infections. Cefotaxime may also be interchangeable with ceftriaxone as off-label use for the treatment of endocarditis by Haemophilus parainfluenzae, H. aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae (HACEK) organisms. Cefotaxime can readily cross the blood-brain barrier when administered intravenously and may treat gram-negative infections that are resistant to previous generations of cephalosporins.
Susceptible organisms include:
Cefotaxime(CTX) exerts its mechanism of action by binding penicillin-binding proteins (PBPs) via beta-lactam rings and inhibiting the definitive activity of transpeptidation in peptidoglycan cell wall synthesis of susceptible bacterial organisms. The inability to form a bacterial cell wall further causes the autolysis of the bacteria.
Beta-lactamases can cause hydrolysis to cefotaxime, further hindering its bactericidal effects. Although susceptive, cefotaxime is quite durable against the activity of most β-lactamases.
Once administered, cefotaxime undergoes metabolism within the liver, and the majority of it is excreted renally. Within the liver, cefotaxime converts to desacetylcefotaxime, which is further converted to desacetylcefotaxime lactone and then to M metabolites. More than 80% is recovered in the urine, with one third being in the form of desacetylcefotaxime (des-CTX). Although desacetylcefotaxime (des-CTX) is the major metabolite of cefotaxime, its activity is eight-fold weaker than cefotaxime.
Cefotaxime is available and distributed in powder form and as a premixed solution for intramuscular and intervenous administration. The powder form is available in 500 mg, 1 g, 2 g, and 10 g vials. The premixed solution is available as 1g and 2g for injection.
Cefotaxime has no coverage for Chlamydia trachomatis, and treatment should be added if this organism is suspected.
Spontaneous Bacterial Peritonitis (SBP):
Moderate to Severe Infections:
Neonates (age 0 to 4 weeks)
Infants and Children (age 1 month to 12 years old)
Individuals with body weight >50 kg should follow adult dosing. The daily dosage should not exceed 12 grams for infants and children.
Local reactions such as pain, swelling, and rash are the most common adverse effects following cefotaxime administration. Like other cephalosporins, cefotaxime does not cause disulfiram-like reactions. Cefotaxime used concurrently with nephrotoxic agents may promote nephrotoxic effects to the kidney, and such use requires caution. Patients with hypersensitivity to cephalosporin or penicillin group may result in an anaphylactic reaction and are manageable with epinephrine, antihistamines, vasopressors, or corticosteroids.
Hypersensitivity to cefotaxime is an absolute contraindication to its use. Patients who have known allergies to penicillin or other cephalosporins should also avoid cefotaxime.
Cefotaxime administration and dosing require adjusting in geriatric populations, patients with decreased renal function, and hepatic dysfunction. Renal function and liver enzymes require routine monitoring. The half-life of cefotaxime is generally one hour, and severe kidney dysfunction may prolong the half-life of cefotaxime and its metabolite desacetylcefotaxime. CBC should also be monitored with cefotaxime use as there are reports of hematologic changes such as neutropenia, leukopenia, and agranulocytosis. Cefotaxime, like other cephalosporins, may also cause a false positive direct coombs test.
Cefotaxime is i FDA Pregnancy Category B drug. Cefotaxime use in pregnancy has not been studied clearly and should be used with caution.
Cefotaxime(CTX) is metabolized by the liver and excreted through the kidneys, and dysfunctions may result in decreased drug clearance resulting in increased plasma concentrations. About 50 to 60% of the agent is excreted in unchanged form, and 15 to 20% is excreted as a desacetyl metabolite desacetylcefotaxime. Toxicity may result in convulsions, dyspnea, hypothermia, cyanosis, reversible encephalopathy, and death. Mortality has occurred with dosages of 6000 mg/kg/day. Treatment for cefotaxime toxicity requires supportive management.
Cefotaxime is a broad-spectrum antibiotic that is FDA-approved and indicated for the treatment of gram-positive, gram-negative, and anaerobic organisms of susceptible strains causing pneumonia, urinary tract infections, cervicitis, endometritis, urethritis, and sepsis. The care for patients suffering from infectious diseases prompts critical care from an interprofessional team of healthcare professionals as preventable contagious disorders can lead to medication resistance, complications, and mortality. These healthcare professionals include a primary care physician, an infectious disease specialist, a gynecologist, a nurse, and a pharmacist.
The primary care physicians and specialists should educate the patients about the consequences of non-compliance of therapy for the full duration, and how resistance to treatment can further cause complications and result in mortality. The primary care physician should routinely monitor renal function, liver enzymes, and CBC as cefotaxime is metabolized and cleared in the liver and kidneys, respectively, and have also shown to cause hematologic adverse effects. Counseling and careful monitoring are necessary during pregnancy, as clinical studies during its use in pregnancy are limited, and cefotaxime FDA pregnancy category B. Physicians should be up to date with the newly FDA approved cefotaxime indications, dosing, and their effects in the event drug resistance do develop.
During treatment of gonorrhea causing urethritis or cervicitis treatment for chlamydia should be added as cefotaxime does not have coverage for this organism. Interprofessional communication is key to building patient rapport and developing a therapeutic alliance, so the patients comply with therapy adequately to eradicate the bacteria and prevent further spread. Continued communication and teamwork between healthcare professionals will improve antimicrobial stewardship, which, in turn, will improve patient outcomes, limit microbial resistance, and lower incidence of multidrug-resistant organisms.
|||Dudley MN,Barriere SL, Cefotaxime: microbiology, pharmacology, and clinical use. Clinical pharmacy. 1982 Mar-Apr; [PubMed PMID: 6309465]|
|||Todd PA,Brogden RN, Cefotaxime. An update of its pharmacology and therapeutic use. Drugs. 1990 Oct; [PubMed PMID: 2083516]|
|||Carmine AA,Brogden RN,Heel RC,Speight TM,Avery GS, Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1983 Mar; [PubMed PMID: 6303743]|
|||Plosker GL,Foster RH,Benfield P, Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. PharmacoEconomics. 1998 Jan; [PubMed PMID: 10175990]|
|||Brogden RN,Spencer CM, Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections. Drugs. 1997 Mar; [PubMed PMID: 9074846]|
|||Baddour LM,Wilson WR,Bayer AS,Fowler VG Jr,Bolger AF,Levison ME,Ferrieri P,Gerber MA,Tani LY,Gewitz MH,Tong DC,Steckelberg JM,Baltimore RS,Shulman ST,Burns JC,Falace DA,Newburger JW,Pallasch TJ,Takahashi M,Taubert KA, Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 Jun 14; [PubMed PMID: 15956145]|
|||Bui T,Preuss CV, Cephalosporins 2020 Jan; [PubMed PMID: 31855361]|
|||Lassman HB,Coombes JD, Metabolism of cefotaxime: a review. Diagnostic microbiology and infectious disease. 1984 Jun; [PubMed PMID: 6086216]|
|||LeFrock JL,Prince RA,Leff RD, Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime. Pharmacotherapy. 1982 Jul-Aug; [PubMed PMID: 6302641]|
|||Coombes JD, Metabolism of cefotaxime in animals and humans. Reviews of infectious diseases. 1982 Sep-Oct; [PubMed PMID: 6294781]|
|||Chin NX,Neu HC, Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. Diagnostic microbiology and infectious disease. 1984 Jun; [PubMed PMID: 6086215]|